Method of treatment for uterine leiomyoma
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsYukio Katsuki, Minoru Shimora
Life of this patent
Estimating the term…
Abstract
Providing a therapeutic agent of uterine leiomyoma, containing dienogest and a solvate thereof as the effective ingredient with less adverse effects, which can be used either singly or in combination with GnRH and can be administered or pharmaceutically manufactured as oral, transdermal dosing agents or suppositories.
Claims11
A method of reducing the recurrence of uterine leiomyoma comprising administering to a patient in need thereof a pharmaceutical composition containing an effective amount of dienogest or a pharmaceutically acceptable solvate thereof as an effective component and a pharmaceutically acceptable carrier.
A method of treating uterine leiomyoma comprising administering to a patient in need thereof a pharmaceutical composition containing an effective amount of dienogest or a pharmaceutically acceptable solvate thereof as an effective component and a pharmaceutically acceptable carrier.
A method of treatment of uterine leiomyoma comprising administering to a patient in need thereof a pharmaceutical composition containing dienogest or a pharmaceutically acceptable solvate thereof in combination with agents selected from the group consisting of gonadotropin releasing hormone agonists, gonadotropin releasing hormone antagonists, antiestrogen agents and aromatase inhibitors and a pharmaceutically acceptable carrier.
A method of reducing the recurrence of uterine leiomyoma comprising administering to a patient in need thereof a pharmaceutical composition containing dienogest or a solvate thereof in combination with agents selected from the group consisting of gonadotropin releasing hormone agonists, gonadotropin releasing hormone antagonists, antiestrogen agents and aromatase inhibitors and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.